Office of the Clinical Director

点击翻译按钮获取中文摘要

In 2021/2022, the Office of the Clinical Director (OCD), Intramural Research Program (IRP), National Institute on Drug Abuse (NIDA), NIH provides clinical research support to (6) independent Laboratories/Clinical investigators, (4 Tenure Track/Unit Chiefs and 2 Senior Investigators/Branch Chiefs) and a recently formerly Core/Facility Head. In January 2022, both the Clinical Director and the Deputy Clinical Director stepped down and an Acting Clinical Director and Acting Deputy Clinical Director were appointed. Operational changes including personnel and workflow are currently underway including the transfer of the Pharmacy to the Administrative Management Branch. The current Clinical research portfolio at the NIDA IRP includes a wide variety of collaborative investigation that focus on: Safety and efficacy of new treatments for addiction. Factors that impact drug taking and relapse. Application of MRI-based structural and functional imaging to elucidate acute and chronic drug effects and their consequences on cognitive processes. Molecular genetic bases of individual differences in vulnerability to develop dependence on an addictive substance. Development of advanced functional and structural magnetic resonance imaging/spectroscopy techniques. Structural MRI techniques to assess tissue integrity related to brain dysfunction. Transcranial magnetic Stimulation (TMS) in the elucidation and treatment of addictive disorders. Mobile health applications for real-time in-the-field addiction treatment interventions.